



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

Mail Stop 4546

November 1, 2016

Via E-mail

Timothy C. Scott

President

Provectus Biopharmaceuticals, Inc.

7327 Oak Ridge Hwy.

Knoxville, Tennessee 37931

**Re: Provectus Biopharmaceuticals, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed October 5, 2016
File No. 001-36457**

Dear Mr. Scott:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

/s/ Joseph McCann for

Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance

cc: Tonya Mitchem Grindon, Esq.
Lori B. Metrock, Esq.
Baker, Donelson, Bearman, Caldwell & Berkowitz, PC